Mayne Pharma Appoints New President

Mayne Pharma Group Limited

has named Stefan Cross as president of Mayne Pharma USA. Cross is responsible for leading all of Mayne Pharma’s existing business operations and overseeing the expansion of Mayne Pharma’s pharmaceutical products division. In addition, Cross will manage the continued growth of contract pharmaceutical services as provided by Mayne Pharma’s subsidiary, Metrics.

Previously, Cross served as Mayne Pharma’s vice-president of business and corporate development, and played a role in the global commercialization of the company’s SUBACAP anti-fungal product. He has been involved inintegrating Metrics with Mayne Pharma, and in executing the company’s business strategy in Australia and the US. Cross headed marketing efforts in the Asia Pacific region for Hospira and led Hospira’s commercial operations in China, Hong Kong, and Taiwan. Prior to that, Cross worked for six years with Mayne Pharma Limited in Europe and Australia, and eight years with F.H. Faulding & Co. Limited.

Cross succeeds Phil Hodges, who founded Metrics and currently serves on the board of directors of Mayne Pharma Group Limited.

Source:

Mayne Pharma Group Limited